Genetics and prescription opioid use (GaPO): study design for consenting a cohort from an existing biobank to identify clinical and genetic factors influencing prescription opioid use and abuse.
Addiction
Genetics
Opioid use disorder (OUD)
Substance misuse
Journal
BMC medical genomics
ISSN: 1755-8794
Titre abrégé: BMC Med Genomics
Pays: England
ID NLM: 101319628
Informations de publication
Date de publication:
26 10 2021
26 10 2021
Historique:
received:
07
07
2021
accepted:
15
10
2021
entrez:
27
10
2021
pubmed:
28
10
2021
medline:
3
3
2022
Statut:
epublish
Résumé
Prescription opioids (POs) are commonly used to treat moderate to severe chronic pain in the health system setting. Although they improve quality of life for many patients, more work is needed to identify both the clinical and genetic factors that put certain individuals at high risk for developing opioid use disorder (OUD) following use of POs for pain relief. With a greater understanding of important risk factors, physicians will be better able to identify patients at highest risk for developing OUD for whom non-opioid alternative therapies and treatments should be considered. We are conducting a prospective observational study that aims to identify the clinical and genetic factors most stongly associated with OUD. The study design leverages an existing biobank that includes whole exome sequencing and array genotyping. The biobank is maintained within an integrated health system, allowing for the large-scale capture and integration of genetic and non-genetic data. Participants are enrolled into the health system biobank via informed consent and then into a second study that focuses on opioid medication use. Data capture includes validated self-report surveys measuring addiction severity, depression, anxiety, and nicotine use, as well as additional clinical, prescription, and brain imaging data extracted from electronic health records. We will harness this multimodal data capture to establish meaningful patient phenotypes in order to understand the genetic and non-genetic contributions to OUD.
Sections du résumé
BACKGROUND
Prescription opioids (POs) are commonly used to treat moderate to severe chronic pain in the health system setting. Although they improve quality of life for many patients, more work is needed to identify both the clinical and genetic factors that put certain individuals at high risk for developing opioid use disorder (OUD) following use of POs for pain relief. With a greater understanding of important risk factors, physicians will be better able to identify patients at highest risk for developing OUD for whom non-opioid alternative therapies and treatments should be considered.
METHODS
We are conducting a prospective observational study that aims to identify the clinical and genetic factors most stongly associated with OUD. The study design leverages an existing biobank that includes whole exome sequencing and array genotyping. The biobank is maintained within an integrated health system, allowing for the large-scale capture and integration of genetic and non-genetic data. Participants are enrolled into the health system biobank via informed consent and then into a second study that focuses on opioid medication use. Data capture includes validated self-report surveys measuring addiction severity, depression, anxiety, and nicotine use, as well as additional clinical, prescription, and brain imaging data extracted from electronic health records.
DISCUSSION
We will harness this multimodal data capture to establish meaningful patient phenotypes in order to understand the genetic and non-genetic contributions to OUD.
Identifiants
pubmed: 34702274
doi: 10.1186/s12920-021-01100-z
pii: 10.1186/s12920-021-01100-z
pmc: PMC8547564
doi:
Substances chimiques
Analgesics, Opioid
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
253Subventions
Organisme : NIDA NIH HHS
ID : R01 DA044015
Pays : United States
Organisme : NIDA NIH HHS
ID : DA044015
Pays : United States
Informations de copyright
© 2021. The Author(s).
Références
Biol Psychiatry. 2008 Feb 1;63(3):256-62
pubmed: 17719014
Am J Psychiatry. 2011 Dec;168(12):1266-77
pubmed: 22193671
Nat Rev Neurosci. 2013 May;14(5):322-36
pubmed: 23531697
Eur J Neurosci. 2020 May;51(9):1928-1943
pubmed: 31605399
JAMA Netw Open. 2021 Jun 1;4(6):e2111826
pubmed: 34115128
JAMA Netw Open. 2021 Apr 1;4(4):e217112
pubmed: 33852004
Br J Addict. 1991 Sep;86(9):1119-27
pubmed: 1932883
J Urban Health. 2020 Dec;97(6):802-807
pubmed: 33005988
Drug Alcohol Depend. 2019 Apr 1;197:78-82
pubmed: 30784952
JAMA Netw Open. 2021 May 3;4(5):e2110452
pubmed: 33978726
Expert Rev Neurother. 2013 Nov;13(11):1221-34
pubmed: 24164053
Genome Res. 2007 Oct;17(10):1520-8
pubmed: 17785532
Nat Hum Behav. 2019 May;3(5):513-525
pubmed: 30962613
Addiction. 1993 Jun;88(6):791-804
pubmed: 8329970
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
JAMA. 2020 Oct 27;324(16):1673-1674
pubmed: 32945832
Surgery. 2020 Apr;167(4):732-742
pubmed: 31349994
Drug Alcohol Depend. 2021 Apr 1;221:108612
pubmed: 33631543
Psychiatry Res Neuroimaging. 2020 Sep 2;305:111174
pubmed: 32920245
J Opioid Manag. 2015 Mar-Apr;11(2):171-83
pubmed: 25901482
Brain. 2010 Jul;133(Pt 7):2098-114
pubmed: 20558415
Biol Psychiatry. 2017 Aug 1;82(3):165-175
pubmed: 28283186
J Am Med Inform Assoc. 2013 Dec;20(e2):e226-31
pubmed: 23956018
Pain. 2011 Aug;152(8):1803-1810
pubmed: 21531077
Psychiatry Res Neuroimaging. 2017 Oct 30;268:22-26
pubmed: 28843088
JAMA Intern Med. 2014 May;174(5):796-801
pubmed: 24589873
Am J Emerg Med. 2020 Apr;38(4):735-740
pubmed: 31227419
MMWR Morb Mortal Wkly Rep. 2011 Nov 4;60(43):1487-92
pubmed: 22048730
JAMA Netw Open. 2020 Sep 1;3(9):e2015909
pubmed: 32886123
Can J Psychiatry. 2011 Aug;56(8):495-502
pubmed: 21878161
JAMA Surg. 2017 Jun 21;152(6):e170504
pubmed: 28403427
JAMA Psychiatry. 2017 Apr 1;74(4):387-398
pubmed: 28146248
NCHS Data Brief. 2020 Nov;(390):1-8
pubmed: 33151145
Science. 2016 Dec 23;354(6319):
pubmed: 28008009
JAMA Psychiatry. 2020 Oct 1;77(10):1072-1080
pubmed: 32492095
Trends Cogn Sci. 2020 Apr;24(4):302-315
pubmed: 32160567
Genet Med. 2016 Sep;18(9):906-13
pubmed: 26866580
JAMA Pediatr. 2020 Feb 1;174(2):141-148
pubmed: 31841589
Am J Hum Genet. 2011 Jul 15;89(1):82-93
pubmed: 21737059
Arterioscler Thromb Vasc Biol. 2021 Jun;41(6):2027-2034
pubmed: 33853351
AIDS Behav. 2019 Dec;23(12):3340-3349
pubmed: 31317364
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Biol Psychiatry. 2014 Jul 1;76(1):66-74
pubmed: 24143882
NPJ Genom Med. 2021 Apr 14;6(1):28
pubmed: 33854068
Subst Abuse Rehabil. 2015 Aug 19;6:83-91
pubmed: 26316838
Mol Psychiatry. 2016 May;21(5):608-14
pubmed: 26239289